Theriva Biologics Interim Filing Shows Loss-Persistent Profile With Narrower Year-Over-Year Reductions And Going-Concern Flag

Bottom line

The interim filing from Theriva Biologics, Inc. (ticker TOVX, CIK 0000894158) was submitted on form 10-Q for fiscal period period-ended-2026-06-30 under accession 0001104659-26-093786, covering both the three-month reporting period the three months ended June 30, 2026 and the six-month year-to-date period the six months ended June 30, 2026, with prior-year comparatives the three months ended June 30, 2025 and the six months ended June 30, 2025 supplied on a consistent basis. The Company's leadership position is that this filing reflects a clinical-stage oncology developer that absorbed the VCN Biosciences platform earlier in its history and is now consolidating a single operating segment covering both the legacy business and the VCN program, with the lead candidate progressing through a Phase II pancreatic study (VIRAGE) and a Phase 1 retinoblastoma study alongside other solid-tumor evaluations.

The reported results for both windows show losses rather than profits. Earnings Per Share, Diluted was a loss of -$0.07 per diluted share USD/SHARES for the three months ended June 30, 2026 and a loss of -$0.12 per diluted share USD/SHARES for the six months ended June 30, 2026, against prior-year losses of -$1.93 per diluted share USD/SHARES for the three months ended June 30, 2025 and -$3.64 per diluted share USD/SHARES for the six months ended June 30, 2025. Operating Income (Loss) mirrored that pattern, with an operating loss of -$3,295,000 USD for the three months ended June 30, 2026 and -$5,422,000 USD for the six months ended June 30, 2026, versus operating losses of -$13,132,000 USD for the three months ended June 30, 2025 and -$17,549,000 USD for the six months ended June 30, 2025. Revenue from Contract with Customer, Excluding Assessed Tax is presented only on the six-month basis at $300,000 USD for the six months ended June 30, 2026. Management also states that the Company continues to experience operating losses, has financed activities principally from equity proceeds since inception, and that these circumstances raise substantial doubt about its ability to continue as a going concern beyond twelve months without additional capital, a strategic transaction, or a licensing arrangement. The filing evidence does not attribute this change to any single cause.

- The Earnings Per Share, Diluted figure is authorized to be stated as higher than the prior period on both the three-month and six-month windows, with the transition described as a loss in both the current and prior periods. - The Operating Income (Loss) figure is likewise authorized to be stated as higher than the prior period on both windows, with the same loss-to-loss transition. - Management attributes the going-concern doubt to the cumulative operating-loss profile and to uncertainty around raising additional debt, equity, license, or partnership proceeds, and explicitly references a Board-approved plan to resize and restructure the Company toward business development and licensing activities while continuing planned clinical work.

Management's own commentary frames the strategic picture as a clinical-stage pivot to oncology with a single-segment structure, while the quantitative outcomes on the income statement remain negative on every window presented and are accompanied by an explicit going-concern flag.

Financial performance

- The quarterly and half-year statements prepared under 10-Q for Theriva Biologics, Inc. in the six months ended June 30, 2026 both report a top-line and bottom-line that the audited FACTs tag as directionally negative: a loss rather than a profit on the operating-income line for both the three months ended June 30, 2026 and the six months ended June 30, 2026, and a loss per diluted share on both windows. The only revenue entry the catalog documents is the half-year-to-date Revenue from Contract with Customer line, which is tagged as positive, not zero — even though R&D-stage clinical companies commonly report de minimis or no revenue, this filing does carry a positive amount for the half-year period.

- Reader-facing comparison: versus the prior-year windows, the authorized direction for Earnings Per Share, Diluted is "increase" but the authorized transition is "loss to loss" on both the three-month and the six-month year-to-date periods, meaning the dilution narrowed directionally while still finishing in the red. The same "increase, loss to loss" pattern is authorized for Operating Income (Loss) on both windows. The filing evidence does not split the change between higher R&D spend, lower R&D spend, higher payroll, lower payroll, or any other line item, so the gap from the prior year is presented as a gap, not a story: The filing evidence does not attribute this change to any single cause..

- Quarter versus the same quarter the prior year: an authorized "increase" on diluted EPS with a "loss to loss" transition, and an authorized "increase" on Operating Income (Loss) with the same "loss to loss" transition. The narrative must stay qualitative — both this quarter and the prior-year quarter are losses, and the directional reading is the only comparison the catalog authorizes. - Half-year versus the prior-year half-year: identical "increase, loss to loss" readings on EPS and on Operating Income (Loss).

Revenue is only cataloged for the current half-year, so any reader-facing line about revenue growth, revenue decline, or revenue mix shift is unsupported; the only safe statement is the positive half-year revenue amount itself. - Accounting context: the filing uses a single operating segment covering the legacy business and the VCN business, and presents the financial statements under a going-concern assumption that management itself flags as substantially doubtful in the cited note. The going-concern disclosure is the accounting context that most directly frames the loss-making P&L — readers should weigh the loss direction against the issuer's stated need for additional capital, debt, or a strategic transaction within the next twelve months, and the workforce reduction and cash-runway extension referenced in the filing.

The filing evidence does not enumerate any peer or industry benchmark for the loss, so no peer comparison is offered: The filing evidence contains no peer or industry comparison.. - Forward-look framing without numeric guidance: management's discussion speaks to pursuing additional equity, debt, or licensing capital, to a contemplated restructuring, and to a runway extending into a stated future quarter, but the catalog does not provide a quantitative forward guidance item, so any reader-facing "guidance" line is restricted to the qualitative direction of those plans — additional capital is being pursued, and the cash runway is described as covering a defined set of activities, not broader operations.

No EPS, revenue, or operating-loss guidance figure is asserted here. - Comparison baseline for the rest of the analysis: the loss-making P&L on both the three-month and six-month windows, the positive half-year revenue line, the going-concern qualification, and the directional "loss to loss" transitions are the only comparison baselines the filing evidence supports for this section.

Operating drivers and segments

- Theriva Biologics, Inc. reports a single operating and reporting segment, combining the legacy business with the VCN business, so segment-level results mirror the consolidated statement of operations and the measure of segment assets is reported on the balance sheet as total consolidated assets. - Revenue from Contract with Customer, Excluding Assessed Tax of $300,000 USD was recognized across the six-month year-to-date period the six months ended June 30, 2026, which is the only revenue line referenced in this section's catalog.

- Operating Income (Loss) was a loss of -$5,422,000 USD for the six-month year-to-date period the six months ended June 30, 2026, compared with a prior-year loss of -$17,549,000 USD for the six months ended June 30, 2025; the year-over-year direction is authorized as an increase (a smaller loss) and the transition is loss to loss. - Operating Income (Loss) was a loss of -$3,295,000 USD for the three-month reporting period the three months ended June 30, 2026, compared with a prior-year loss of -$13,132,000 USD for the three months ended June 30, 2025; the direction is authorized as an increase (a smaller loss) and the transition is loss to loss.

- The contrast between positive top-line activity on the year-to-date window and operating losses on both windows is the operating profile the segment evidence actually supports; The filing evidence does not attribute this change to any single cause.. - Management frames the consolidated result through a clinical-stage narrative rather than a commercial one, identifying Theriva Biologics, Inc. as a diversified clinical-stage developer of therapeutics for cancer and related diseases in areas of high unmet need and describing the strategic transition to oncology through the VCN acquisition referenced in Note 14.

- The lead candidate is described as a clinical-stage oncolytic human adenovirus modified for tumor-selective replication and to express an enzyme intended to break down the tumor stroma barrier; it has been evaluated in the VIRAGE pancreatic-cancer study, in a Phase 1 retinoblastoma study, and in various other Phase 1 studies in additional solid-tumor indications. - Management explicitly casts the financials on a going-concern basis: the company continues to experience operating losses and faces significant uncertainties related to its business model, market conditions, and strategic initiatives, and the ability to continue as a going concern is dependent on raising additional debt and equity capital or securing a licensing or strategic relationship.

- The capital-raising strategy described is active and multi-pronged, encompassing private placements, public offerings, partnerships and other collaborations, alongside a range of strategic alternatives that may include a business combination, merger, or reverse merger, with ongoing discussions named with strategic institutional investors and investment banks. - Other Information items Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5 and Item 6 structure the interim filing and are referenced in the disclosure but do not alter the segment, loss, or going-concern picture above.

- Independent analysis: revenue recognition of $300,000 USD alongside continuing operating losses on both windows, in a single-segment clinical-stage issuer whose own management raises substantial doubt about its ability to continue as a going concern beyond the next twelve months without additional capital or strategic action, supports a narrow read in which the year-to-date top-line line is the only reported commercial activity and the operating result reflects clinical-development spending under that constraint.

Readers comparing this interim to other clinical-stage loss profiles may find additional context in Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction, where a similar loss-persistence pattern is examined. The filing evidence contains no peer or industry comparison.

Cash flow and capital

- Operating activities continued to consume cash, with the six-month year-to-date net cash used in operating activities of -$5,541,000 widening relative to the prior-year comparative of -$9,468,000; both periods recorded outflows rather than inflows, and the filing offers no narrative tying the change to a single driver. - Investing activities likewise registered outflows in both windows. Net cash used in investing activities for the six-month year-to-date period was -$3,000, compared with the prior-year comparative of -$16,000; the absolute spend shifted between the two windows, but the evidence does not attribute the gap to any specific project or asset.

- Capital expenditure detail is reported as payments to acquire property, plant, and equipment of $3,000 for the current six-month year-to-date period and $16,000 for the prior-year comparative, with the current-year figure lower than the prior-year figure; no further breakdown of capex by site or program is provided. - Financing activities were the only positive cash-flow line in both windows. Net cash provided by financing activities was $3,852,000 for the current six-month year-to-date period, lower than the prior-year comparative of $9,883,000, indicating that external funding remained the marginal cash source even as the pace of inflows moderated.

- Management links its funding strategy explicitly to the clinical pipeline, referencing a Phase clinical study for the treatment of retinoblastoma and the broader VCN-X discovery platform cited in the Phase reference, and states that future trials are expected to be larger and more cash-intensive than current efforts. The Company flags that it currently has no third-party capital commitments and lists potential sources, including strategic relationships, public or private equity sales (including through the Amended and Restated At The Market Issuance Sales Agreement), and debt, while warning that ATM availability and terms are not assured.

- The going-concern discussion enumerates factors that could accelerate funding needs — patient recruitment pace, scope of research programs, manufacturing costs, regulatory timing, and intellectual property enforcement — but stops short of quantifying a runway. - On the balance sheet side, Cash and Cash Equivalents, at Carrying Value stood at $11,337,000 as of the balance sheet date of the balance sheet date of June 30, 2026, while Accounts Payable, Current stood at $984,000 at the same date. The disclosed working-capital gap between these two line items frames how quickly available cash could be absorbed by near-term obligations.

- Because the filing is an interim 10-Q for Theriva Biologics, Inc. (TOVX, CIK 0000894158, accession 0001104659-26-093786, fiscal period period-ended-2026-06-30), and operating cash burn continued alongside reduced financing inflows, capital allocation in this window centers on preserving liquidity rather than discretionary investment; the filing references no dividend, repurchase, or strategic M&A activity. - The prior-year comparative balances for the six months ended June 30, 2025 are reported alongside the current the six months ended June 30, 2026 statements, allowing the directional read above without inferring magnitudes.

- Readers comparing pipeline-stage biotechs may find the parallel interim profile in Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction a useful counterpoint for how similar issuers present cash burn and ATM-style financing.

Peer and historical context

Theriva Biologics, Inc. operates as a single segment focused on the discovery and development of oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells, and the filing itself notes that the principal operations are in the United States with long-lived assets located primarily within the United States and Spain. Within the filing evidence for this 10-Q filing covering period-ended-2026-06-30 under accession 0001104659-26-093786 for Theriva Biologics, Inc. (TOVX, CIK 0000894158), there is no named peer company and no industry benchmark disclosed. The quoted narrative only describes Theriva's own CODM structure, performance measures (consolidated net loss and pre-clinical/clinical research goals), and accounting policies; nothing in the passage compares Theriva's revenue, operating result, or cash burn to another issuer or to a sector index. Readers looking for a side-by-side peer table should treat the peer dimension as out of scope for this filing rather than fill the gap with outside data.

On the historical axis, the filing does lay down two prior-period comparatives that frame a year-over-year read. Operating Income (Loss) for the three-month reporting period the three months ended June 30, 2026 was -$3,295,000 USD, against -$13,132,000 USD for the three months ended June 30, 2025, both losses, with the authorized direction indicating an increase (that is, a smaller loss) versus the prior-year quarter. Operating Income (Loss) for the six-month year-to-date period the six months ended June 30, 2026 was -$5,422,000 USD, compared with -$17,549,000 USD for the six months ended June 30, 2025, again both losses, with the same authorized direction toward a smaller loss on the year-to-date window. The half-year cash-flow comparison shows Net Cash Provided by (Used in) Operating Activities of -$5,541,000 USD for the six months ended June 30, 2026 against -$9,468,000 USD for the six months ended June 30, 2025, both negative, with the authorized direction indicating an increase (smaller use of cash) compared with the prior year. Revenue from Contract with Customer, Excluding Assessed Tax was $300,000 USD for the six months ended June 30, 2026, the only top-line value disclosed in the catalog and only for the half-year window, with no prior-year revenue figure supplied, so no authorized historical revenue comparison can be drawn from the catalog.

What the filing evidence does not do is at least as important as what it does. There is no peer-by-peer revenue, margin, pipeline-stage, or market-cap comparison in the quoted text. There is no industry commentary, no competitor disclosure, and no management table positioning Theriva against similar oncology-virus developers. The clinical-stage context is hinted at through the cited Phase 1 reference (a Phase … clinical study for the treatment of retinoblastoma, as well as various other Phase … items), but no peer milestones, approval timelines, or comparable trial readouts are presented. For a cross-filing orientation, readers can compare Theriva's loss-persistent profile to other interim issuers covered on Lizely Finance, such as the Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction, which similarly shows loss-to-loss comparisons across the six-month and three-month windows. Why the operating loss narrowed or why operating cash outflow moved on a year-over-year basis is not addressed by the filing text; The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Scenario analysis

Under the base path for Theriva Biologics, Inc. (TOVX) as disclosed under 10-Q for period-ended-2026-06-30 (0001104659-26-093786), the single operating segment progresses on its existing plan: continued spend on the retinoblastoma program referenced in the cited note alongside other early-stage work in Phase 1, with revenue limited to the six-month year-to-date line of $300,000 USD reported for the six months ended June 30, 2026. The base path keeps the company consuming cash while it advances clinical milestones, with funding needs reflected in the equity activity referenced by Note 14 and standard balance-sheet positioning in the cited notes.

The constructive path assumes the IPR&D and clinical programs advance without impairment charges (none were recorded in the current or prior interim period per the cited accounting policy), milestone-driven consideration tied to the partner program is achieved, and the company accesses capital markets efficiently under Note 14. In that state, the recognized revenue line of $300,000 USD for the six months ended June 30, 2026 would represent a starting platform that could expand as partner product sales occur and as milestone conditions are met, while cost discipline under the segment-budget process the CODM uses keeps the loss trajectory consistent with the authorized direction on the operating loss line. The filing evidence does not attribute this change to any single cause.

The adverse path assumes clinical readouts disappoint or development is terminated, which under the cited IPR&D policy could trigger a full or partial impairment equal to the excess of carrying value over fair value. It also assumes contingent-consideration obligations re-measure upward, capital-markets access narrows, and partner sales fall short of the estimates used to recognize the revenue line of $300,000 USD for the six months ended June 30, 2026. In that state, the Phase 1 program could be paused or wound down, additional equity could be raised on less favorable terms under Note 14, and the company would need to revisit the liquidity planning the CODM relies on. Readers comparing interim biotech loss-persistence patterns can cross-check Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction for context on how similar filings frame downside paths, and the Discounted Payback Period guide is referenced for sizing funding runway under each scenario. The filing evidence contains no peer or industry comparison.

Risks and what to watch

- Reported facts: The interim financial statements identify a revenue line tied to contracts with customers for the six-month year-to-date period of $300,000 USD. The accompanying notes describe in-progress research and development assets considered indefinite-lived until a development project either reaches regulatory approval and commercialization or is terminated or abandoned. The notes also flag that, during the period that IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis on a date in October or more frequently if the Company becomes aware of events or changes in circumstances that could indicate an impairment, with any impairment recognized as the excess of carrying value over fair value. The notes on contingent consideration describe an obligation whose subsequent fair-value changes flow through the consolidated statements of operations and whose earn-out reassessment occurs at each balance sheet date.

- Management explanations: Management frames the indefinite-lived IPR&D treatment as tied to completion or abandonment of the associated research and development projects and to the ability to commercialize products linked to those assets. Management also frames contingent consideration as a milestone-driven liability whose future earn-out probabilities are re-evaluated periodically.

- Analyst inference: Together, these notes point to two balance-sheet exposures where the next reporting periods could move headline metrics without any change in revenue. First, an IPR&D outcome — a positive regulatory milestone moving assets from indefinite-lived to amortizable, or a negative outcome producing an impairment — would change amortization schedules or trigger a charge. Second, a reassessment of contingent consideration could swing the operating result through fair-value adjustments, leaving the top line flat while bottom-line direction shifts. Both channels sit inside the interim disclosure for this 10-Q covering period-ended-2026-06-30 under accession 0001104659-26-093786 for Theriva Biologics, Inc. (TOVX, CIK 0000894158).

- Counter-evidence: The only top-line fact cited in the ledger is revenue under customer contracts for the six-month period, with no segment or geographic breakout beyond the note that principal operations are in the United States and that long-lived assets sit primarily in the United States and Spain. Year-over-year operating income for the half-year window and quarter window is recorded as a loss in both the current and prior periods, an authorized direction that does not speak to magnitude or to whether the gap is narrowing or widening. Investors wanting a comparable interim-filing baseline of a peer with a similar loss posture can cross-check Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction.

- Unknowns: The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison. Causality behind any change discussed above is not attributed to a single driver in the quoted notes. The filing evidence does not attribute this change to any single cause.

- Metrics to watch next period: the next revenue figure for the year-to-date window, the status of the retinoblastoma program and any other Phase efforts referenced in Phase 1, the carrying value of indefinite-lived IPR&D and the result of the next annual impairment test in October, the fair-value of contingent consideration at the next balance-sheet date, the change in common stock disclosures referenced in Note 14, and any updates under Item 1A within Item 1, together with Item 2, Item 3, Item 4 and the signature and exhibits sections captured by Item 6 through Item 5.